Hong Kong Stock Movement

DIAGENS-B surged 20.12%. Based on recent key news:

1. On August 18, DIAGENS-B announced a strategic cooperation agreement with a well-known AI company, significantly boosting its stock price. The collaboration aims to enhance retail business efficiency using AI technology, and the market reacted positively, with the stock price rising by 20.12%;

2. On August 17, DIAGENS-B released its latest financial report, showing that its second-quarter performance exceeded market expectations. The report indicated a year-on-year revenue growth of 30% and a net profit increase of 25%, with strong financial performance boosting investor confidence and driving the stock price up;

3. On August 16, analysts raised the target price for DIAGENS-B, anticipating significant future growth potential. Several well-known brokerages released reports suggesting that DIAGENS-B's positioning in the new retail and AI sectors will yield long-term benefits, thus uplifting the stock price. The prospects in the new retail and AI sectors are broad, with noticeable capital inflow.

Stocks with High Trading Volume in the Industry

MicroPort Medical rose 6.41%. Based on recent news:

1. On August 19, MicroPort Medical issued a performance forecast, expecting a year-on-year revenue growth of approximately 12% to 14% for its continuing operations in the first half of the year, with overseas business contributing about 140% growth. Although net losses have widened, the market still holds expectations for its future profitability, driving the stock price up.

2. On August 19, the company previously accepted loans from Hillhouse Capital and other parties and signed a betting agreement. According to the agreement, MicroPort Medical needs to achieve at least USD 140 million in net profit in the second half of the year to fulfill the betting terms, increasing market attention on its performance.

3. Recently, MicroPort Medical's trading volume has significantly increased, reaching HKD 52.19 million, indicating investor interest and confidence in the stock. The overall performance of the medical industry is good, with noticeable capital inflow.

MicroPort Robotics-B rose 5.64%. Based on recent key news:

1. On August 17, the direction for refined management of medical insurance was clarified, and the charging standards for surgical robots were made clear, providing a basis for the company's long-term planning, which boosted the stock price. Source: KeChuangBan Daily

2. On August 17, analysts gave MicroPort Robotics-B a buy rating, with a target price of HKD 45, enhancing market confidence. Source: TipRanks

3. On August 17, the board of MicroPort Robotics-B will review the interim performance and possible interim dividends on August 27, with expected positive impacts driving the stock price up. Source: Hong Kong Stock Exchange. The long-term outlook for the medical robotics industry is optimistic, with a rational market rebound after a short-term adjustment.

Angelalign rose 0.16%. Based on recent news:

1. On August 18, Angelalign released a forecast for its 2026 semi-annual report, indicating a year-on-year growth of 43.3% in invisible orthodontic cases in overseas markets. This growth reflects the company's successful expansion in international markets and patent layout, driving the stock price up

2. On August 17, American invisible aligner manufacturer Align Technology released its Q2 2026 financial report, disclosing the progress of its patent litigation with Angelalign. The Zhengzhou Intermediate Court's first-instance ruling determined that Angelalign did not constitute infringement, boosting market confidence and leading to a rise in stock prices.

3. On August 18, an industry report indicated that the orthodontics market in China is steadily growing, with an expected compound annual growth rate of 14.4% from 2024 to 2028. This optimistic industry outlook further supports Angelalign's stock performance. The orthodontics market is steadily growing, with a positive outlook.

Stocks ranked among the top in industry market capitalization

Zhenjiankang Medical-B rose by 0.31%. Based on recent key news:

1. On June 30, Zhenjiankang Medical was listed on the Hong Kong Stock Exchange, becoming the "first stock of percutaneous surgical robots," with its stock price rising over 200% on the first day of listing, and its market capitalization exceeding HKD 14 billion. This event significantly increased market attention and confidence in the company, driving up its stock price.

2. Recently, orthopedic surgical robot Tianzhihang disclosed plans to acquire a 62% stake in Shanghai MicroPort Orthopedics Medical Technology Co., Ltd. This "snake swallowing elephant" deal has been referred to by the market as "the largest acquisition in the surgical robot field this year," highlighting the defensive strategies of related companies in response to industry competition and further enhancing market confidence in the surgical robot industry.

3. Advances in xenotransplantation technology, particularly the success of gene-modified pig lung transplants in humans, have driven market demand for organ perfusion devices. Zhenjiankang Medical's multi-organ perfusion platform has completed productization and scenario validation, with vast market potential, enhancing investors' expectations for the company's future growth potential. Competition in the surgical robot industry is intensifying, and significant progress in xenotransplantation technology is evident